Background: Adjuvant trastuzumab in combination with chemotherapy improves survival of women with HER2-positive early breast cancer. In this study, we compared 12 versus 6 months of adjuvant trastuzumab. Results: A total of 481 patients were randomized to receive 12 months (n = 241) or 6 months (n = 240) of adjuvant trastuzumab. Chemotherapy was completed in 99% and 98% of patients, while trastuzumab therapy in 100% and 96% of patients in the 12-and 6-month groups, respectively. After 47 and 51 months of median follow-up, there were 17 (7.1%) and 28 (11.7%) disease relapses in the 12-and 6-month groups (P = 0.08). The 3-year DFS was 95.7% versus 93.3% in favor of the 12-month treatment group (hazard ratio = 1.57; 95% confidence interval 0.86-2.10; P = 0.137). There was no difference in terms of overall survival and cardiac toxicity between the two groups.
introduction Approximately 15%-20% of invasive breast carcinomas have amplification of the human epidermal growth factor receptor 2 gene (Her2-neu) and overexpress the HER2 protein [1] . Before the development of the anti-HER2-targeted therapies, women with early HER2-positive breast cancer faced a worse prognosis in terms of both disease-free (DFS) and overall survival (OS) [1] .
Three large randomized trials produced convincing evidence that the anti-HER2 monoclonal antibody trastuzumab, administered with adjuvant chemotherapy for 12 months, increases DFS and OS of women with HER2-positive operable breast cancer [2] [3] [4] . From two of the studies, the NCCTG N9831 and the NSABP B-31, a remarkable increase in 10-year OS from 75.2% to 84% was recently reported [5] . Similarly, significant clinical benefit with adjuvant trastuzumab after chemotherapy was confirmed in the most recent report of the HERA trial [6] .
In the above studies, the choice of 12-month treatment duration for trastuzumab was mostly arbitrary, rather than based on pre-existing evidence. Consequently, the optimal duration of treatment with adjuvant trastuzumab has been unclear, especially after the report of the FinHer trial, which showed that when trastuzumab is administered concomitantly with chemotherapy for just 9 weeks, the reduction in the risk of relapse appears similar to longer treatment [7] . A shorter period of trastuzumab administration would be an attractive option for obvious reasons, like reduced toxicity and cost as well as, convenience to patients.
To address this question, the Hellenic Oncology Research Group (HORG) conducted a randomized study to compare the efficacy of 12 versus 6 months of adjuvant trastuzumab administered concurrently with dose-dense chemotherapy in women with node-positive or high-risk node-negative early breast cancer.
patients and methods
This randomized study was conducted at participating sites of HORG. The protocol was approved by the institutional review boards and the independent ethics committees. The study was conducted in compliance with Good Clinical Practice and the Declaration of Helsinki. Written informed consent was required from all patients to enter the study.
Women 18-75 years old with histologically confirmed invasive early breast cancer with HER2 overexpression were eligible. The HER2-positive status was determined by local pathology laboratories using immunohistochemistry and/or fluorescence in situ hybridization when appropriate and according to international standards. Patients were required to have undergone either lumpectomy or modified radical mastectomy with tumor-free surgical margins plus axillary node dissection, and the tumor had to be invasive carcinoma with at least one positive axillary node. In May 2008, the HORG scientific committee amended the protocol and women with highrisk node-negative disease were allowed to participate in the study. Adequate hematologic, hepatic, renal parameters, and cardiac function were mandatory. The latter was evaluated by echocardiogram or multigated acquisition scan (MUGA); the left-ventricular ejection fraction (LVEF) was required to be more than 50%. Patients with a previous history of invasive breast cancer were ineligible, as were patients with history of another malignancy within 5 years other than nonmelanoma skin cancer.
treatment
A central randomization procedure, using computer software was carried out after surgery and before the initiation of any adjuvant treatment to assign patients in an one-to-one ratio to receive either 12 
end points
The primary end point of the study was to compare the 3-year DFS rates between the two trastuzumab-treated groups. The DFS was defined as the time from randomization to the date of breast cancer recurrence (either locoregional or distant), contralateral breast cancer diagnosis, nonbreast second primary cancer, or death from any cause, whichever occurred first.
Patients alive without any predefined event were censored at the time of last assessment. Secondary end points were to compare OS (defined as the time from the date of randomization to death from any cause) and toxicity. The Common Terminology Criteria for Adverse Events of the National Cancer Institute version 3.0 were used for toxicity grading.
statistical analysis
The null hypothesis of the trial was that 6 months of adjuvant trastuzumab is not inferior to 12-month treatment by a prespecified acceptable margin in terms of 3-year DFS. The noninferiority hazard ratio (HR) margin of 1.53 was derived from an estimated absolute difference in 3-year DFS of 8%, based on an expected DFS in the 12-month group of 85%. To reject the null hypothesis and therefore to conclude on noninferiority, the upper bound of the 95% confidence interval (CI) should be less than this margin. With a type I error of 5% and 80% power, 239 patients were required to enroll on each arm within an accrual period of 3 years. Stratification parameters for the random assignment were the menopausal status ( pre-versus post-), the number of infiltrated axillary lymph nodes (0 versus 1-3 versus 4-10 versus >10) and hormone receptor status [estrogen (ER) and/or progesterone receptor (PR) positive versus both negative]. All patients who received at least one cycle of treatment were included in the analysis. The DFS and OS rates were calculated using the Kaplan-Meier method. The comparison of treatment arms was assessed using the log-rank test. The independent effect of treatment and other prognostic factors on DFS and OS was analyzed by Cox's proportional hazards model. (Figure 1 ; CONSORT diagram of the study). The two patient groups were well-balanced regarding their prognostic characteristics (Table 1 ). The only difference was the slightly older median age of women in the 6-month treatment group (56 versus 54 years, P = 0.008). Approximately 21% of the patients had node-negative disease, while 14% had more than 10 infiltrated axillary nodes. The tumor expressed ER, PR, or both in roughly 67% of patients and was negative for both in 33%.
treatment
The proportion of women who received all eight cycles of chemotherapy was 99.6% versus 97.9% for the 12-and 6-month groups (P = 0.112), respectively. Treatment-related adverse events was the only reason for chemotherapy discontinuation. These were an allergic reaction to docetaxel (n = 1), febrile neutropenia with skin rash (n = 1), atrial fibrillation (n = 1), hepatitis (n = 1), neutropenia grade III with asthenia (n = 1). The proportion of women who completed the postchemotherapy trastuzumab was 100% versus 96.2% for the 12-and 6-month groups (P = 0.002), respectively. The reasons for trastuzumab discontinuation were patient refusal to continue (n = 4), atrial fibrillation (n = 1), hepatitis (n = 1), borderline LVEF of 50% (n = 1), local complication of surgery required a second procedure (n = 1), and early disease relapse (n = 1).
disease-free and overall survival
After a median follow-up of 47 and 51 months, 17 (7.1%) and 28 (11.7%) patients had disease recurrence in the 12-and 6-month group, respectively (P = 0.08). The majority of patients experienced a distant relapse (15 and 21 in the 12-and 6-month groups, respectively), 1 patient in the 12-month group developed contralateral breast cancer, while 6 patients in the 6-month group developed locoregional recurrence. Ten (4.1%) and eight (3.3%) patients had died (P = 0.6) in the 12-and 6-month groups, respectively, with all but one death in each arm to be related to breast cancer. Although the median DFS has not yet been reached, there was no significant difference between the 12-and the 6-month treated groups (HR = 1.57; 95% CI 0.86-2.10; P = 0.137). Figure 2A illustrates the Kaplan-Meier curves for DFS in the two treatment groups. The 3-year DFS rates were 95.7% and 93.3% for the 12-and 6-month groups, respectively. Similarly, there was no difference in the OS between the two groups (P = 0.436; Figure 2B ). A univariate forest plot including patient, disease, and treatment characteristics related to DFS is illustrated in Figure 3 .
adverse events
A summary of clinically relevant grade II-IV toxicities is presented in Table 2 . Serious adverse events were very rare. Early stopping of postchemotherapy trastuzumab due to toxicities was not reported in the 12-month group and occurred in only two patients (0.8%) in the 6-month group. These interruptions were due to atrial fibrillation and decreased LVEF to 50% in two patients. Cardiac toxicity did not differ between the two arms. No toxic deaths were reported.
discussion
The decision to administer adjuvant trastuzumab for a 12-month period was based on no pre-existing evidence, but more or less on what investigators felt would be both acceptable and effective for patients. Consequently, the optimal duration of treatment with adjuvant trastuzumab has remained unclear. In metastatic disease, withholding trastuzumab in a responding patient almost always leads to disease progression. This observation supports trastuzumab administration for a long period. Conversely, in early breast cancer, two small studies suggested that when trastuzumab is administered concomitantly with chemotherapy for 9 weeks to 6 months, the reduction in the risk of relapse is similar to longer treatment [7] [8] [9] .
The HERA trial compared 1-year versus 2-year trastuzumab added sequentially to adjuvant chemotherapy and found no additional benefit for the 2-year regimen [10] . The question whether 6 months of adjuvant trastuzumab is noninferior to 12 months of treatment in women with early HER2-positive breast cancer was investigated in the PHARE study [11] . Patients received at least four cycles of chemotherapy, before being randomized to 6 (n = 1690) or 12 months (n = 1690) of trastuzumab. The primary end point was DFS with a prespecified noninferiority HR margin of 1.15. After a median follow-up of 42.5 months, DFS events occurred in 175 patients in the 12-month group (10.4%) and 219 patients in the 6-month group (13.0%). Two-year DFS was 93.8% in the 12-month group and 91.1% in the 6-month group. Since the estimated HR of 1.28 (95% CI 1.05-1.56, P = 0.29 for noninferiority) did not meet the prespecified margin of 1.15, it could not be concluded that the 6-month regimen was noninferior. Fewer patients in the 12-month group had distant recurrences (6.4% versus 8.3%, HR = 1.33, 95% CI 1.04-1.71). Among patients with ER-negative tumors who received sequential chemotherapy and trastuzumab, DFS was significantly shorter in patients of the 6-month group compared with those of the 12-month group (HR = 1.57, 95% CI 1.08-2.28). Cardiac events were significantly more common in the 12-month group (5.7% versus 1.9%, P < 0.0001). The investigators concluded that the PHARE trial did not show that 6 months of adjuvant trastuzumab is noninferior to 12 months administration and despite the increased risk of cardiac events with longer treatment duration, 12 months of trastuzumab was recommended as the standard of care in this setting.
Our study failed to demonstrate noninferiority for the 6-months of adjuvant trastuzumab versus the standard 12-month administration as well. On the other hand, the 6-month regimen was not proven to be inferior compared to the longer regimen either and, therefore, the study is inconclusive on the primary end point. However, the computed HRs between the treatment groups suggest a DFS benefit and support the current standard of care of adjuvant trastuzumab administration for 12 months. These results are in agreement with those of PHARE trial. Despite the limitation of lack of a conventional noninferiority study design, we believe that our trial builds upon what we have learnt from the PHARE study. Most importantly, it further supports the underlying biology of ER and ability to respond to treatment. In patients with ER-negative tumors who received concomitant chemotherapy and trastuzumab both in ours and in the PHARE trial, the HR estimate of 6 versus 12 months of trastuzumab was compatible with the noninferiority hypothesis ( Figure 3 ; HR = 1.14, 95% CI 0.48-2.69 and HR = 1.10, 95% CI 0.73-1.65, respectively). Therefore, in this group of 'pure' HER2-positive tumors, most of the adjuvant effects might occur early during therapy, possibly during the concomitant administration of chemotherapy and trastuzumab. On the contrary, in the PHARE trial, patients with ER-negative tumors who received trastuzumab sequential to chemotherapy derived more benefit from the prolonged trastuzumab administration. In our study, the benefit of longer trastuzumab administration almost reached statistical significance (HR = 2.20, 95% CI 0.91-5.31) for patients with ER-positive tumors (Figure 3) . Although this subgroup analysis should be interpreted with caution because it was not prespecified and the 95% CI is wide, our results further support previous data on the sensitivity of double-positive tumors (for ER and HER-2) to combined HER2-targeting and endocrine therapy [12] [13] [14] . The randomization before adjuvant chemotherapy avoided the exclusion of patients who did not complete adjuvant chemotherapy or who recurred early on, thus preventing a selection bias. Finally, the chemotherapy backbone was unique for all patients in our study and was administered in a dose-dense fashion, which became the standard of care in the United States after the publication of the CALGB 9741 trial in 2003 [15] . Our group has also been successfully using this regimen for patients with high-risk HER2-negative early breast cancer [16] .
Our study has certain limitations that should be considered when interpreting analyzing our data into clinical practice. The number of patients enrolled is relatively small and the noninferiority margin set by the statistical hypothesis relatively large. However, it is not unusual for oncology studies to adopt a wide noninferiority margin in order to facilitate the answer of clinically important questions [17] . Moreover, the study was hampered by slow accrual and eventually took 8 years to be completed instead of the planned 3 years and would have been benefited by an independent review committee which unfortunately was not involved. The two arms were well balanced for the all the stratification parameters; however, although age was not a stratification factor older patients were actually randomized on the 6-month group. Also, surprisingly more patients in the 6-month group failed to complete the adjuvant trastuzumab treatment, primarily due to patients' refusal to continue treatment. Is there any patients' group for which shorter administration of adjuvant trastuzumab may be enough? To address this question we need to define which early-stage HER2-positive breast cancers have a sufficiently favorable prognosis to enable the shorter administration of trastuzumab. Recently, two studies provided relevant data. The Kaiser Permanente study reported DFS rates of 99% and 97% for patients with T1a and T1b disease respectively, in a trastuzumab-naive cohort, with almost all distant recurrences (six of eight events) occurring in women with tumors at the 1-cm threshold [18] . Similarly, women of a National Comprehensive Cancer Network cohort had not been treated with chemotherapy/trastuzumab, had a 5-year DFS ranged from 93% to 96% [19] . These results support that women with small, node-negative tumors have a favorable long-term outcome and if adjuvant therapy is prescribed, then 6 months of trastuzumab might be a reasonable option. Moreover, in a recent the PHARE trial's date the treatment effect was evaluated according to tumors' characteristics and four prognostic groups were defined (very-low, low, intermediate and high) [20] . For the very-low-risk patients treated with 6-month of adjuvant trastuzumab, the 3-year DFS of 98.3% was highly convincing that the absolute benefit of standard duration of trastuzumab is clinically questionable. Similarly, in the HERA trial, the absolute benefit of 0.6% in terms of 3-year DFS for the patients with node-negative, hormone receptor-negative disease indicates that for these patients 6 months of adjuvant trastuzumab might be reasonable [21] . Another option for patients at low risk of relapse is to combine trastuzumab with a less intense chemotherapy regimen. The excellent outcome of patients with stage I disease treated with adjuvant weekly paclitaxel and standard duration trastuzumab [22] is in favor of this approach.
In conclusion, our results support the current standard of care of 12 months adjuvant trastuzumab for women with early HER2-positive breast cancer. Whether a shorter course of trastuzumab is enough for specific subgroups (e.g. ER-negative tumors, small tumors) needs to be addressed in a pooled analysis of PHARE, ours and other ongoing trials including PERSEPHONE (NCT00712140) and SHORT-HER (NCT00629278).
acknowledgements
We thank Dora Hatzidaki and Vasso Athanasaki for their assistance in data analysis and the preparation of this manuscript.
funding
The studies supported by HORG (no grant number). disclosure 
